Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 19/20 | 0.67 |
| ▸ | THRA | P10827 | 19/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.65 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.65 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22632565 | 0.92 | THRB (0.66) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL23828936 | 0.92 | THRB (0.58) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL23259871 | 0.91 | THRB (0.59) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL23828949 | 0.91 | THRB (0.57) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL16919814 | 0.88 | THRA (0.68) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632660 | 0.87 | THRB (0.56) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749523 | 0.86 | THRA (0.67) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749414 | 0.86 | THRA (0.67) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL24032552 | 0.86 | THRB (0.70) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL23828944 | 0.85 | THRB (0.50) | THRBTHRACYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138971-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | ROYAL PHARMA (IN) | 2026-05-21 | — | — | US | claimed |
| EP-4691557-A2 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | Madrigal Pharmaceuticals, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| CN-119504714-A | Rasemet-teh preparation method of herba Luo | 河北科技大学 | 2025-02-25 | — | — | CN | claimed |
| CN-118388412-A | Method for preparing 6- (4-amino-2, 6-dichlorophenoxy) -4-isopropyl pyridazin-3 (2H) -ketone | 四川伊诺达博医药科技有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-118388413-A | Method for preparing 6- (4-amino-2, 6-dichlorophenoxy) -4-isopropyl pyridazin-3 (2H) -ketone | 成都伊诺达博医药科技有限公司 | 2024-07-26 | — | — | CN | claimed |
| EP-4023641-B1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | MADRIGAL PHARMACEUTICALS INC (US) | 2024-05-01 | — | — | EP | claimed |
| WO-2024084491-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | MEHTA NILESH VIPINCHANDRA (IN) | 2024-04-25 | — | — | WO | claimed |
| EP-4023641-A2 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | Madrigal Pharmaceuticals, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| US-10894050-B2 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | MADRIGAL PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | claimed |
| CN-105008335-B | Method for synthesizing thyroid hormone analogue and its polymorph | 马德里加尔制药公司 | 2018-12-21 | — | — | CN | claimed |
| US-9266861-B2 | Method of synthesizing thyroid hormone analogs and polymorphs thereof | MADRIGAL PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | claimed |
| US-20150203473-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2015-07-23 | — | — | US | claimed |
| EP-2895466-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | Madrigal Pharmaceuticals, Inc. (US) | 2015-07-22 | — | — | EP | claimed |
| WO-2014043706-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | MADRIGAL PHARMACEUTICALS, INC. (US) | 2014-03-20 | — | — | WO | claimed |
| US-20260138971-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | ROYAL PHARMA (IN) | 2026-05-21 | — | — | US | disclosed |
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-112805005-B | Thyroxine receptor beta agonist compounds | 拓臻股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20070032494-A1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007009913-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009913-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138971-A1 | PROCESS FOR SYNTHESIS OF RES METIROM AND ITS INTERMEDIATES THEREOF | CARM1, DAO, CA2 | THRB 153/4885THRA 286/4885CYP2C9 222/4885 |
| US-10894050-B2 | Methods of synthesizing thyroid hormone analogs and polymorphs thereof | THRB, TSHR, TRHR | THRB 1/4885THRA 4/4885CYP2C9 270/4885 |
| US-20070032494-A1 | Thyroid hormone analogs | THRA, THRB, TPO | THRB 2/4885THRA 1/4885CYP2C9 746/4885 |
| US-20150203473-A1 | METHOD OF SYNTHESIZING THYROID HORMONE ANALOGS AND POLYMORPHS THEREOF | THRB, TSHR, TRHR | THRB 1/4885THRA 4/4885CYP2C9 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.